These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles. Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406 [TBL] [Abstract][Full Text] [Related]
7. Plant-derived virus-like particles as vaccines. Chen Q; Lai H Hum Vaccin Immunother; 2013 Jan; 9(1):26-49. PubMed ID: 22995837 [TBL] [Abstract][Full Text] [Related]
8. Establishment of a yeast-based VLP platform for antigen presentation. Wetzel D; Rolf T; Suckow M; Kranz A; Barbian A; Chan JA; Leitsch J; Weniger M; Jenzelewski V; Kouskousis B; Palmer C; Beeson JG; Schembecker G; Merz J; Piontek M Microb Cell Fact; 2018 Feb; 17(1):17. PubMed ID: 29402276 [TBL] [Abstract][Full Text] [Related]
9. Next generation vaccines and vectors: Designing downstream processes for recombinant protein-based virus-like particles. Effio CL; Hubbuch J Biotechnol J; 2015 May; 10(5):715-27. PubMed ID: 25880158 [TBL] [Abstract][Full Text] [Related]
10. Virus-like particles produced in plants as potential vaccines. Scotti N; Rybicki EP Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411 [TBL] [Abstract][Full Text] [Related]
11. Enveloped virus-like particle platforms: vaccines of the future? Pitoiset F; Vazquez T; Bellier B Expert Rev Vaccines; 2015 Jul; 14(7):913-5. PubMed ID: 25968245 [TBL] [Abstract][Full Text] [Related]
13. The application of virus-like particles as vaccines and biological vehicles. Yan D; Wei YQ; Guo HC; Sun SQ Appl Microbiol Biotechnol; 2015 Dec; 99(24):10415-32. PubMed ID: 26454868 [TBL] [Abstract][Full Text] [Related]
14. Biomolecular engineering of virus-like particles aided by computational chemistry methods. Zhang L; Lua LH; Middelberg AP; Sun Y; Connors NK Chem Soc Rev; 2015 Dec; 44(23):8608-18. PubMed ID: 26383145 [TBL] [Abstract][Full Text] [Related]
15. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Chuan YP; Rivera-Hernandez T; Wibowo N; Connors NK; Wu Y; Hughes FK; Lua LH; Middelberg AP Biotechnol Bioeng; 2013 Sep; 110(9):2343-51. PubMed ID: 23532896 [TBL] [Abstract][Full Text] [Related]
16. Virus-like particles: potential veterinary vaccine immunogens. Liu F; Ge S; Li L; Wu X; Liu Z; Wang Z Res Vet Sci; 2012 Oct; 93(2):553-9. PubMed ID: 22100244 [TBL] [Abstract][Full Text] [Related]
17. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease. Shen H; Xue C; Lv L; Wang W; Liu Q; Liu K; Chen X; Zheng J; Li X; Cao Y Virus Res; 2013 Dec; 178(2):430-6. PubMed ID: 24050994 [TBL] [Abstract][Full Text] [Related]
19. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Zhao Q; Li S; Yu H; Xia N; Modis Y Trends Biotechnol; 2013 Nov; 31(11):654-63. PubMed ID: 24125746 [TBL] [Abstract][Full Text] [Related]
20. Advances in influenza virus-like particles bioprocesses. Durous L; Rosa-Calatrava M; Petiot E Expert Rev Vaccines; 2019 Dec; 18(12):1285-1300. PubMed ID: 31829068 [No Abstract] [Full Text] [Related] [Next] [New Search]